These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 210975)

  • 1. Beneficial action of new angiotensin-converting enzyme inhibitor (SQ 14,225) in hemorrhagic shock in cats.
    Trachte GJ; Lefer AM
    Circ Res; 1978 Oct; 43(4):576-82. PubMed ID: 210975
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of the protective effect of angiotensin-converting enzyme inhibition in hemorrhagic shock.
    Trachte GJ; Lefer AM
    Proc Soc Exp Biol Med; 1979 Oct; 162(1):54-7. PubMed ID: 228313
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of angiotensin II receptor blockade by [Sar1-Ala8]angiotensin II in hemorrhagic shock.
    Trachte GJ; Lefer AM
    Am J Physiol; 1979 Feb; 236(2):H280-5. PubMed ID: 311160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of anisodamine in hemorrhagic shock.
    Su J; Hock CE; Lefer AM
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Apr; 325(4):360-5. PubMed ID: 6728045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhagic shock in cats.
    Freeman JG; Hock CE; Edmonds JS; Lefer AM
    J Pharmacol Exp Ther; 1984 Dec; 231(3):610-5. PubMed ID: 6094795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salutary effects of nitrendipine, a new calcium entry blocker, in hemorrhagic shock.
    Hock CE; Su JY; Lefer AM
    Eur J Pharmacol; 1984 Jan; 97(1-2):37-46. PubMed ID: 6698110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective actions of naloxone in hemorrhagic shock.
    Curtis MT; Lefer AM
    Am J Physiol; 1980 Sep; 239(3):H416-21. PubMed ID: 7435587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of AVP in maintenance of circulatory homeostasis during hemorrhagic shock.
    Hock CE; Su JY; Lefer AM
    Am J Physiol; 1984 Feb; 246(2 Pt 2):H174-9. PubMed ID: 6696129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats.
    Vollmer RR; Boccagno JA
    Eur J Pharmacol; 1977 Sep; 45(2):117-25. PubMed ID: 198216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial actions of nalorphine during hemorrhagic shock in cats.
    Hock CE; Curtis MT; Jaffe JS; Lefer AM
    Proc Soc Exp Biol Med; 1983 May; 173(1):76-81. PubMed ID: 6304745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin-converting enzyme inhibitor (SQ 20881) on the plasma concentration of angiotensin I, angiotensin II, and arginine vasopressin in the dog during hemorrhagic shock.
    Morton JJ; Semple PF; Ledingham IM; Stuart B; Tehrani MA; Garcia AR; McGarrity G
    Circ Res; 1977 Sep; 41(3):301-8. PubMed ID: 890886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of ethylketocyclazocine in hemorrhagic shock.
    Curtis MT; Lefer AM
    Adv Shock Res; 1983; 10():101-9. PubMed ID: 6308972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial action of a new opiate antagonist (Win 44,441-3) in hemorrhagic shock.
    Curtis MT; Lefer AM
    Eur J Pharmacol; 1982 Mar; 78(3):307-13. PubMed ID: 6279411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inadequacy of steroids in the treatment of severe hemorrhagic shock.
    Raflo GT; Jones RC; Wangensteen SL
    Am J Surg; 1975 Sep; 130(3):321-7. PubMed ID: 1166920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine and the intestinal response to hemorrhagic shock.
    Rosenfeld LM
    Circ Shock; 1979; 6(2):137-45. PubMed ID: 455595
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of angiotensin converting enzyme inhibitor SQ 14,225 on the blood pressure, renin-angiotensin-aldosterone system and renal function in patients with malignant hypertension (author's transl)].
    Shionoiri H; Uneda S; Tochikubo O; Ohonishi T; Harada J; Sesoko S; Goto E; Fujishima S; Kaneko Y
    Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):13-22. PubMed ID: 6247528
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute Bradykinin Receptor Blockade During Hemorrhagic Shock in Mice Prevents the Worsening Hypotensive Effect of Angiotensin-Converting Enzyme Inhibitor.
    Charbonneau H; Buléon M; Minville V; Faguer S; Girolami JP; Bascands JL; Tack I; Mayeur N
    Crit Care Med; 2016 Sep; 44(9):e882-5. PubMed ID: 26992065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the lack of a beneficial response to inotropic drugs in hemorrhagic shock.
    Lefer AM; Glenn TM; Lopez-Rasi AM; Kiechel SF; Ferguson WW; Wangensteen SL
    Clin Pharmacol Ther; 1971; 12(3):506-16. PubMed ID: 5567802
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of suppression of endocrine or exocrine pancreatic function in hemorrhagic shock.
    Galvin MJ; Lefer AM
    Experientia; 1979 Jan; 35(1):55-6. PubMed ID: 369876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.